• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Adherence to adjuvant endocrine therapy for breast cancer: a qualitative exploration of attribution of symptoms among post-menopausal women.乳腺癌辅助内分泌治疗的依从性:绝经后妇女症状归因的定性探讨。
Support Care Cancer. 2024 Apr 2;32(4):265. doi: 10.1007/s00520-024-08463-w.
2
Deconstructing Decisions to Initiate, Maintain, or Discontinue Adjuvant Endocrine Therapy in Breast Cancer Survivors: A Mixed-Methods Study.解析乳腺癌幸存者启动、维持或终止辅助内分泌治疗的决策:一项混合方法研究。
Oncol Nurs Forum. 2017 May 1;44(3):E101-E110. doi: 10.1188/17.ONF.E101-E110.
3
Are breast cancer patients with suboptimal adherence to cardiovascular treatment more likely to discontinue adjuvant endocrine therapy? Competing risk survival analysis in a nationwide cohort of postmenopausal women.乳腺癌患者心血管治疗依从性差是否更有可能停止辅助内分泌治疗?基于全国绝经后女性队列的竞争风险生存分析
BMC Med. 2023 Nov 24;21(1):463. doi: 10.1186/s12916-023-03156-3.
4
The Patient's Voice: Adherence, Symptoms, and Distress Related to Adjuvant Endocrine Therapy After Breast Cancer.患者的声音:乳腺癌辅助内分泌治疗的依从性、症状与痛苦
Int J Behav Med. 2020 Dec;27(6):687-697. doi: 10.1007/s12529-020-09908-2.
5
Women with breast cancer's perceptions of nurse-led telephone-based motivational interviewing consultations to enhance adherence to adjuvant endocrine therapy: a qualitative study.乳腺癌女性对护士主导的基于电话的动机性访谈咨询以增强辅助内分泌治疗依从性的看法:一项定性研究。
Support Care Cancer. 2022 Jun;30(6):4759-4768. doi: 10.1007/s00520-021-06692-x. Epub 2022 Feb 8.
6
Racial Differences in Patient-Reported Symptoms and Adherence to Adjuvant Endocrine Therapy Among Women With Early-Stage, Hormone Receptor-Positive Breast Cancer.早期激素受体阳性乳腺癌女性患者报告的症状和辅助内分泌治疗依从性的种族差异。
JAMA Netw Open. 2022 Aug 1;5(8):e2225485. doi: 10.1001/jamanetworkopen.2022.25485.
7
Understanding pain related to adjuvant endocrine therapy after breast cancer: A qualitative report.理解乳腺癌辅助内分泌治疗相关疼痛:一项定性报告。
Eur J Cancer Care (Engl). 2022 Nov;31(6):e13723. doi: 10.1111/ecc.13723. Epub 2022 Oct 4.
8
A telehealth intervention for symptom management, distress, and adherence to adjuvant endocrine therapy: A randomized controlled trial.一项针对症状管理、困扰和辅助内分泌治疗依从性的远程医疗干预:一项随机对照试验。
Cancer. 2022 Oct 1;128(19):3541-3551. doi: 10.1002/cncr.34409. Epub 2022 Aug 4.
9
Testing a behavioral intervention to improve adherence to adjuvant endocrine therapy (AET).测试一种改善辅助内分泌治疗(AET)依从性的行为干预措施。
Contemp Clin Trials. 2019 Jan;76:120-131. doi: 10.1016/j.cct.2018.11.010. Epub 2018 Nov 22.
10
Factors influencing adherence to adjuvant endocrine therapy in breast cancer-treated women: using real-world data to inform a switch from acute to chronic disease management.影响乳腺癌治疗后女性接受辅助内分泌治疗依从性的因素:利用真实世界数据为从急性疾病管理向慢性疾病管理的转变提供信息。
Breast Cancer Res Treat. 2020 Aug;183(1):189-199. doi: 10.1007/s10549-020-05748-6. Epub 2020 Jun 26.

本文引用的文献

1
Identifying determinants of adherence to adjuvant endocrine therapy following breast cancer: A systematic review of reviews.确定乳腺癌辅助内分泌治疗依从性的决定因素:系统评价综述。
Cancer Med. 2024 Feb;13(3):e6937. doi: 10.1002/cam4.6937. Epub 2024 Jan 19.
2
A Systematic Review and Meta-Analysis of Interventions to Promote Adjuvant Endocrine Therapy Adherence Among Breast Cancer Survivors.一项促进乳腺癌幸存者辅助内分泌治疗依从性的干预措施的系统评价和荟萃分析。
J Clin Oncol. 2023 Oct 1;41(28):4548-4561. doi: 10.1200/JCO.23.00697. Epub 2023 Aug 2.
3
Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.《NCCN 肿瘤学临床实践指南:乳腺癌》第 3.2022 版
J Natl Compr Canc Netw. 2022 Jun;20(6):691-722. doi: 10.6004/jnccn.2022.0030.
4
Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR Early-stage Breast Cancer for 10 Years of Endocrine Therapy.乳腺癌指数预测可延长内分泌获益,以实现 HR 早期乳腺癌患者个体化选择接受 10 年内分泌治疗。
Clin Cancer Res. 2021 Jan 1;27(1):311-319. doi: 10.1158/1078-0432.CCR-20-2737. Epub 2020 Oct 27.
5
Adherence to adjuvant endocrine therapy among breast cancer survivors: a systematic review and meta-synthesis of the qualitative literature using grounded theory.乳腺癌幸存者辅助内分泌治疗的依从性:基于扎根理论的系统评价和定性文献荟萃分析。
Support Care Cancer. 2020 Nov;28(11):5075-5084. doi: 10.1007/s00520-020-05585-9. Epub 2020 Jun 29.
6
Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer.早期乳腺癌患者辅助内分泌治疗 10 年与 5 年的临床结局比较。
BMC Cancer. 2018 Oct 12;18(1):977. doi: 10.1186/s12885-018-4878-4.
7
Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03).患者报告的早期治疗中断预测因素:NCIC 临床试验组(CCTG)MA.27(E1Z03)中随机分配至阿那曲唑或依西美坦的绝经后女性原发性乳腺癌的与治疗相关的症状和健康相关的生活质量。
Breast Cancer Res Treat. 2018 Jun;169(3):537-548. doi: 10.1007/s10549-018-4713-2. Epub 2018 Feb 17.
8
Identifying the determinants of adjuvant hormonal therapy medication taking behaviour in women with stages I-III breast cancer: A systematic review and meta-analysis.确定I-III期乳腺癌女性辅助激素治疗用药行为的决定因素:一项系统评价和荟萃分析。
Patient Educ Couns. 2015 May 30. doi: 10.1016/j.pec.2015.05.013.
9
Understanding patients' adherence-related beliefs about medicines prescribed for long-term conditions: a meta-analytic review of the Necessity-Concerns Framework.理解患者对长期疾病所开药物的依从性相关信念:必要性-担忧框架的荟萃分析综述
PLoS One. 2013 Dec 2;8(12):e80633. doi: 10.1371/journal.pone.0080633. eCollection 2013.
10
Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review.临床实践中乳腺癌幸存者辅助激素治疗的依从性:系统评价。
Breast Cancer Res Treat. 2012 Jul;134(2):459-78. doi: 10.1007/s10549-012-2114-5. Epub 2012 Jun 12.

乳腺癌辅助内分泌治疗的依从性:绝经后妇女症状归因的定性探讨。

Adherence to adjuvant endocrine therapy for breast cancer: a qualitative exploration of attribution of symptoms among post-menopausal women.

机构信息

Medical College of Wisconsin, 8701 W Watertown Plank Rd, Milwaukee, WI, 52336, USA.

出版信息

Support Care Cancer. 2024 Apr 2;32(4):265. doi: 10.1007/s00520-024-08463-w.

DOI:10.1007/s00520-024-08463-w
PMID:38565669
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11698022/
Abstract

PURPOSE

Oral adjuvant endocrine therapy (AET) is an effective treatment for hormone receptor positive breast cancer to decrease recurrence and mortality, but adherence is poor. This study explored post-menopausal women's experiences with AET, with a particular focus on adherence to AET as well as distress and symptoms experienced prior to and during AET treatment.

METHODS

Participants were recruited from a hospital registry, stratified by adherence to/discontinuation of AET. Telephone interviews followed a semi-structured interview guide and were recorded and transcribed verbatim. Transcripts were systematically coded using team-based coding, with analysis of themes using a grounded theory approach.

RESULTS

Thirty-three participants were interviewed; ages ranged from 57 to 86 years. Participants included 10 discontinued patients and 23 patients who completed their AET course or were adherent to AET at the time of interviewing. Both adherent and discontinued patients reported symptoms throughout their AET treatment course, and both attributed symptoms to factors other than AET (e.g., older age and pre-existing comorbidities). However, discontinued patients were more likely to attribute symptoms to AET and to describe difficulty managing their symptoms, with some directly citing symptoms as the reason for discontinuing AET therapy. Conversely, adherent patients were more likely to describe the necessity of taking AET, despite symptoms.

CONCLUSIONS

AET adherence was associated with beliefs about AET, symptom attribution, and symptom management. Routine symptom monitoring during AET and addressing both symptoms and patients' understanding of their symptoms may promote adherence to AET.

摘要

目的

口服辅助内分泌治疗(AET)是治疗激素受体阳性乳腺癌的有效方法,可以降低复发和死亡风险,但患者的依从性较差。本研究探讨了绝经后妇女接受 AET 的体验,特别关注 AET 的依从性以及在接受 AET 治疗之前和期间经历的痛苦和症状。

方法

参与者从医院登记处招募,根据 AET 的依从性/中断情况进行分层。电话访谈遵循半结构化访谈指南,并进行录音和逐字转录。使用基于团队的编码对转录本进行系统编码,并使用扎根理论方法分析主题。

结果

共访谈了 33 名参与者,年龄在 57 至 86 岁之间。参与者包括 10 名中断治疗的患者和 23 名完成 AET 疗程或在访谈时依从 AET 的患者。依从和中断治疗的患者均报告在整个 AET 治疗过程中出现症状,并且都将症状归因于 AET 以外的因素(例如,年龄较大和预先存在的合并症)。然而,中断治疗的患者更有可能将症状归因于 AET,并描述难以管理其症状,有些患者直接将症状作为中断 AET 治疗的原因。相反,依从治疗的患者更可能描述尽管有症状但仍需要服用 AET。

结论

AET 的依从性与对 AET 的信念、症状归因和症状管理有关。在 AET 期间进行常规症状监测,并解决症状和患者对其症状的理解,可能会促进对 AET 的依从性。